NCT00179686已完成2 期
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 12
- 主要终点
- To determine the activity of lenalidiomide in recurrent non-small cell lung cancer. Activity will be assessed by measuring the response rate, tumor control rate, and time to tumor progression.
研究概览
简要总结
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Understand and voluntarily sign an informed consent form.
- •Age >or = to 18 years at the time of signing the informed consent form
- •Able to adhere to the study visit schedule and other protocol requirements
- •Must have a histologically confirmed diagnosis of non small cell lung cancer that has recurred following at least two prior regimens. Those regimens must have contained both a platinum compound and a taxane either sequentially or in combination
- •Subjects must have measurable disease on cross sectional imaging that is at least 2 cm in the longest diameter.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 (see Appendix II).
- •Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
- •WCBP must agree to have pregnancy tests every 4 weeks while on study drug (every 14 days for women with irregular cycles) and 4 weeks after the last dose of study drug.
排除标准
- •Any of the following laboratory abnormalities:
- •Absolute neutrophil count (ANC) <1,500 cells/mm3 (1.5 x 109/L)
- •Platelet count <100,000/mm3 (100 x 109/L)
- •Serum creatinine >2.5 mg/dL (221 mmol/L)
- •Serum SGOT/AST or SGPT/ALT >5.0 x upper limit of normal (ULN)
- •Serum total bilirubin >2.0 mg/dL (34 mmol/L)
- •Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- •Prior history of malignancies other than non-small cell lung cancer (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for > or = to 1 year.
- •Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- •Pregnant or lactating females.
- •Prior > or = grade 3 allergic reaction/hypersensitivity to thalidomide.
- •Prior > or = grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
- •Prior use of lenalidomide.
- •Use of any standard/experimental anti-cancer drug therapy within 28 days of the initiation of study drug therapy.
结局指标
主要结局
To determine the activity of lenalidiomide in recurrent non-small cell lung cancer. Activity will be assessed by measuring the response rate, tumor control rate, and time to tumor progression.
次要结局
- To evaluate the safety of lenalidomide monotherapy as treatment for subjects with recurrent non-small cell lung cancer.
研究者
研究点 (12)
Loading locations...
相似试验
终止
2 期
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.Prostate CancerNCT00179738Celgene Corporation40
已完成
2 期
A Study of Revlimid in the Treatment of Non-Hodgkin's LymphomaLymphoma, Non-Hodgkin'sNCT00413036Celgene217
已完成
2 期
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaNon-Hodgkins LymphomaNCT00179673Celgene43
已完成
2 期
Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic AbnormalityMyelodysplastic SyndromesNCT00065156Celgene148
终止
2 期
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's LymphomaT-cell Non-Hodgkin's LymphomaNCT00655668Celgene54